The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® ...

Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca PLC securities between February 23, 2022 and December ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

At AstraZeneca, an early adopter of AI and data ... illustrating the myriad ways electrons can join together to form a frictionless quantum soup. Charlie Wood WIRED is where tomorrow is realized.

AstraZeneca CFO Aradhana Sarin promised Phase III readouts and revenue growth in 2025 despite ongoing investigations of its Chinese operations. Credit: Bloomberg/ Getty Images AstraZeneca says a ...

Supplementary forms are required for the following schools in addition to the completion of your home local authority application form. The below options link to the individual school's website.

AstraZeneca's first-in-class severe asthma ... and not restricted to those with forms of the disease tied to specific characteristics such as high levels of eosinophils. AZ's head of biopharma ...

The application process, including exploring immigration programs, documents you may need, how to apply and what to do while you wait for a decision.

Download and save the PDF to your computer Open the downloaded PDF in Acrobat Reader 10 or later Use this form if you are the legal representative for an estate, business, or property, and you are ...